Corporate News
Page 3
Jun 01, 2023
Simplifying AI data analysis for scientists – as REPROCELL, IBM and STFC Hartree Centre successfully launch Pharmacology-AI platform
REPROCELL has collaborated with HNCDI to create a machine learning (ML) platform that simplifies and accelerates the analysis of big data from drug development studies.
May 25, 2023
[PRESS RELEASE] Announcement of Results of Phase II Clinical Trial in Japan for Stemchymal®, a Regenerative Medicine Product for Spinocerebellar Ataxia
[PRESS RELEASE] Announcement of Results of Phase II Clinical Trial in Japan for Stemchymal®, a Regenerative Medicine Product for Spinocerebellar Ataxia
May 23, 2023
REPROCELL offers mesenchymal stem cell based CDMO services to manufacture Advanced Therapies Medicinal Products
REPROCELL will now offer CDMO services to manufacture ATMPs generated from mesenchymal stem cells (MSC) through a partnership with Histocell.
May 04, 2023
End of Q4 update from REPROCELL (2022-23)
Did you know that REPROCELL is celebrating its 20th anniversary this year? If you missed the commemorative letter from our CEO you can find out more here.
May 03, 2023
Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial
REPROCELL USA has been awarded a contract to provide support for Lantern Pharma’s Phase 2 clinical trial entitled “HARMONIC”.
Feb 28, 2023
Celebrating the 20th Anniversary of REPROCELL: A letter from our CEO Chikafumi Yokoyama
On February 26 2023 REPROCELL celebrated its 20th anniversary. In this letter, the company CEO reflects on the history of REPROCELL to the present day.
Dec 12, 2022
End of Q3 update from REPROCELL (2022-23)
The final months of 2022 have brought new collaborations, partnerships, and successes to enrich your stem cell and drug discovery research.
Dec 09, 2022
Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue
The three-month study, conducted at REPROCELL, will assess the binding affinity of the peptide in healthy human and RA synovial tissue.
Nov 23, 2022
REPROCELL invests in Histocell, S.L. a Spain-based CDMO
REPROCELL Inc. decided to invest in Histocell S.L. to strengthen its clinical induced pluripotent stem cell (iPSC) service offerings.
Nov 09, 2022
Building economic resilience and unleashing productivity through digital innovation
CEO of REPROCELL said his company was among those that had received support from HNCDI to help it develop new approaches to drug development.
Oct 13, 2022
REPROCELL Inc. and JTB Corp. form a business alliance to provide Personal iPS Service to domestic and overseas customers
REPROCELL Inc. and JTB Corp. will begin marketing Personal iPS (REPROCELL's iPSC storage and production service) overseas through the JMHC.
Oct 05, 2022
REPROCELL Inc. and CIRM sign MOU for special access to clinical iPSCs
Learn why REPROCELL Inc. has agreed to join the California Institute for Regenerative Medicine’s (CIRM) Industry Resource Partner Program.
Oct 04, 2022
REPROCELL and BioBridge Global sign Memorandum of Understanding to accelerate global manufacturing services using clinical iPSCs
REPROCELL and Texas-based BioBridge Global have signed a Memorandum of Understanding to enhance their strategic collaborative relationship. Find out more.
Oct 03, 2022
End of Q2 update from REPROCELL (2022-23)
Read the end of Q2 update from REPROCELL for the financial year 2022-23. Discover the latest website updates, blog, and news updates.
Aug 31, 2022
REPROCELL, IBM and STFC harness the power of AI in drug discovery and precision medicine
Collaboration at Hartree NCDI combines REPROCELL’s tests of drug efficacy in human living tissues with IBM expertise in AI and machine learning.
Aug 17, 2022
Preclinical studies by REPROCELL give COPD drug a final boost before clinical trials
Learn how scientists at REPROCELL compared the effects of RCD405 with drugs that are currently used to treat respiratory disease in human living bronchi.
Aug 15, 2022
Life science after lockdown: SPS returns for 2022
Discover the first, in-person Saftey Pharmacology Society annual meeting since 2019: a dynamic forum, known for its global networking opportunities.
Aug 09, 2022
Bioserve India granted NABL accreditation in the field of Genomics Testing
Bioserve Biotechnologies India Pvt Ltd has received NABL accreditation for Medical Testing in the field of Genomics Testing Services.
May 16, 2022
Completion of Clinical Phase II Trials of Stemchymal in Japan
We will endeavor to obtain clinical approval as soon as possible so that we can provide the new treatment to patients suffering from this disease.
Mar 08, 2022
REPROCELL co-author paper with IBM showcasing a novel ML driven precision medicine strategy for drug development
Read how REPROCELL and IBM developed a novel Machine Learning driven precision medicine strategy for drug development.